Adipocyte/macrophage fatty acid binding proteins in metabolic syndrome

被引:37
作者
Erbay E. [1 ]
Cao H. [1 ]
Hotamisligil G.S. [1 ]
机构
[1] Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA 02115
基金
美国国家卫生研究院;
关键词
Metabolic Syndrome; Fatty Acid Binding Protein; Foam Cell Formation; Systemic Insulin Resistance; Scd1 Expression;
D O I
10.1007/s11883-007-0023-6
中图分类号
学科分类号
摘要
The link between inflammation and the development of insulin resistance, type 2 diabetes, and atherosclerosis has been uncovered in the past decade. Although the molecular mechanisms underlying the co-occurrence of these metabolic and inflammatory diseases are not fully understood, several molecular players, integrating stress and inflammatory responses with metabolic homeostasis, were discovered recently. One of these molecular integration sites is through the action of cytosolic lipid chaperones or fatty acid binding proteins (FABPs), which are common to adipocytes and macrophages. Furthermore, studies in a variety of genetic models demonstrated that the FABPs aP2 and mal1 are critical mediators of many components of metabolic syndrome in mice. These exciting findings raise the possibility that FABPs represent desirable therapeutic targets for metabolic syndrome. In this review, we describe the findings demonstrating FABP's role in metabolic and inflammatory diseases and highlight recent advances in understanding the mechanisms of FABP function at the cellular and molecular level. © 2007 by Current Medicine Group LLC.
引用
收藏
页码:222 / 229
页数:7
相关论文
共 48 条
[1]
Hotamisligil G.S., Inflammation and metabolic disorders, Nature, 444, pp. 860-867, (2006)
[2]
Semenkovich C.F., Insulin resistance and atherosclerosis, J Clin Invest, 116, pp. 1813-1822, (2006)
[3]
Wellen K.E., Hotamisligil G.S., Inflammation, stress, and diabetes, J Clin Invest, 115, pp. 1111-1119, (2005)
[4]
Makowski L., Hotamisligil G.S., The role of fatty acid binding proteins in metabolic syndrome and atheroselerosis, Curr Opin Lipidol, 16, pp. 543-548, (2005)
[5]
Tuncman G., Erbay E., Hom X., Et al., A functional genetic variant at the fatty acid binding protein, aP2, locus reduces the risk for hypertriglyceridemia, type 2 diabetes and cardivascular disease, Proc Natl Acad Sci U S A, 103, pp. 6970-6975, (2005)
[6]
Tubas I., Consequences of cellular cholesterol accumulation: Basic concepts and physiological implications, J Clin Invest, 110, pp. 905-911, (2002)
[7]
Funk C.D., Prostaglandins and leukotrienes: Advances in eicosanoid biology, Science, 294, pp. 1871-1875, (2001)
[8]
Stumvoll M., Goldstein B.J., van Haeften T.W., Type 2 diabetes: Principles of pathogenesis and therapy, Lancet, 365, pp. 1333-1346, (2005)
[9]
Esteves A., Ehrlich R., Invertebrate intracellular fatty acid binding proteins, Comp Biochem Physiol C Toxicol Pharmacol, 142, pp. 262-274, (2006)
[10]
Chmurzynska A., The multigene family of fatty acid-binding proteins (FABPs): Function, structure and polymorphism, J Appl Genet, 47, pp. 39-48, (2006)